Physician profile
Samiya Yasin
NPI 1700236197
$1,273.24
in general payments reported to CMS, 2019-2025
14 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $433 · 2024: $514 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.20 |
| Education | $172.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $470.24 | 2023-2025 | Farxiga, Lokelma |
| Veloxis Pharmaceuticals, INC. | $396.26 | 2023-2025 | Envarsus |
| Nxstage Medical, INC. | $92.10 | 2023-2024 | Nxstage System One, Nxstage Pureflow Solution |
| Alexion Pharmaceuticals, INC. | $70.12 | 2024-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $62.94 | 2023-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.13 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $23.49 | 2025 | Benlysta |
| Ardelyx, INC. | $22.55 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $21.24 | 2025 | Jynarque |
| Travere Therapeutics, INC. | $18.53 | 2025 | Filspari |
| Calliditas Therapeutics US INC. | $17.77 | 2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $16.99 | 2024 | Purified Cortrophin Gel |
| Medtronic, INC. | $16.65 | 2023 | Venaseal |
| Bayer Healthcare Pharmaceuticals INC. | $16.23 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samiya Yasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.